J
Jose Luiz Pedrini
Publications - 21
Citations - 6768
Jose Luiz Pedrini is an academic researcher. The author has contributed to research in topics: Breast cancer & Pertuzumab. The author has an hindex of 13, co-authored 18 publications receiving 5500 citations.
Papers
More filters
Journal ArticleDOI
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M Swain,Sandra M Swain,David Miles,Sung Bae Kim,Young-Hyuck Im,Seock-Ah Im,Vladimir Semiglazov,Eva Ciruelos,Andreas Schneeweiss,Sherene Loi,Estefania Monturus,Emma Clark,Adam Knott,Eleonora Restuccia,Mark C. Benyunes,Javier Cortes,Richy Agajanian,Rizvana Ahmad,Bahriye Aktas,Victor Hugo Alencar,Dino Amadori,Jurandyr Andrade,Fabio Franke,Catia Angiolini,Kenjiro Aogi,Jess Armor,Wichit Arpornwirat,Laura Assersohn,William Audeh,Walter E. Aulitzky,Sergio J Azevedo,Maria Alejandra Bartoli,Norberto Batista Lopez,María Bianconi,Laura Biganzoli,Ruemu E. Birhiray,Marianna Bitina,Ron Blachy,Kimberly L. Blackwell,Rita Blanchard,Paulette Blanchet,Ion Boiangiu,Barbara Bower,Christine Brezden-Masley,Adam Brufsky,Leanne Budde,Priscilla Caguioa,Lourdes Calvo,Mario Campone,Robert R. Carroll,Hugo Castro,Valorie Chan,Veena Charu,Saverio Cinieri,Michael R. Clemens,Emilio Alba Conejo,Eduardo Côrtes,Bruno Coudert,Eduardo Cronemberger,Daniel Cubero,Shaker R. Dakhil,Brooke R. Daniel,Neville Davidson,Maria De Fatima Gaui,Susana De La Cruz,Maria Del Pilar,Gilson Delgado,John Allan Ellerton,Cesar Estuardo,Louis Fehrenbacher,Jean-Marc Ferrero,Patrick J. Flynn,Malgorzata Foszczynska-Kloda,Sandra Franco,Hirofumi Fujii,Chris Gallagher,Teresa Gamucci,Nora Giacomi,Miguel Gil I Gil,Antonio Gonzalez Martin,Vera Gorbunova,Eugeny Gotovkin,Nathan B. Green,Elza Grincuka,Eva-Maria Grischke,Vincent Hansen,Jeffrey Hargis,Maik Hauschild,Roberto Hegg,Carolyn B. Hendricks,Robert Hermann,Paulo M. Hoff,Jun Horiguchi,Javier Hornedo Muguiro,Stefano Iacobelli,Kenichi Inoue,Gustavo Ismael,Yoshinori Itoh,Hiroji Iwata,Davi Jendiroba,Rosa Jochim,Alison Jones,Marianne Just,Andre Kallab,Mark Karwal,Masahiro Kashiwaba,Giraldo Kato,Peter A. Kaufman,Pirkko Kellokumpu-Lehtinen,Andreas Kirsch,Igor Kiselev,Paula Klein,Norio Kohno,Mikhail Kopp,Liljana Kostovska-Maneva,Mauricio Kotliar,Iveta Kudaba,Sherko Kümmel,Katsumasa Kuroi,Juan Lacava,Luciano Latini,Soo-Chin Lee,Mikhail Lichinitser,Christopher Lobo,Christoph Maintz,Jedzada Maneecahvakajorn,Alexander Marmé,Gloria Martinez,Norikazu Masuda,Mario Matwiejuk,Vladimir Merculov,Richard A. Michaelson,Luis Miguel,Hernandez Monroy,Filippo Montemurro,Serafin Morales,Rodrigo Moura,Volkmar Mueller,Clive Mulatero,Kazuhiko Nakagami,Takahiro Nakayama,Jeff Neidhart,An Nguyen,Reiki Nishimura,Haruki Ogata,S O'Reilly,Timothy J. O'Rourke,Douglas Otero Reye,Xuenong Ouyang,Ravi Patel,Taral Patel,Jose Luiz Pedrini,Rodrigo Pereira,Alejandra Perez,Carol Peterson,Tadeusz Pienkowski,Helio Pinczowski,Jonathan Polikoff,Wojciech Polkowski,Paola Edith Price,Sue Prill,Frank Priou,Gunta Purkalne,Seppo Pyrhoenen,Robert Quackenbush,Yoshiaki Rai,Nuria Ribelles,Jungsil Ro,Anne Robinson,Robert Robles,Gladys Rodriguez,L Roman,Shigehira Saji,Pedro Sánchez-Rovira,Nobuaki Sato,Marcus Schmidt,Claudia Schumacher,Frank Senecal,Priyanka Sharma,Zhenzhou Shen,Vadim Shirinkin,Edda Simoncini,Thitiya Sirisinha,Raymond Smith,Joohyuk Sohn,Zeljko Soldic,Tania Soria,Darcy Spicer,Vichien Srimuninnimit,Virote Sriuranpong,Elżbieta Starosławska,Petar Stefanovski,Patrapim Sunpaweravong,Julie Taguchi,Koji Takeda,Gabriel Tellez-Trevilla,Randall Thomas,Christoph Thomssen,Zetina Toache,Yutaka Tokuda,Piotr Tomczak,Celia Tosello,Koichiro Tsugawa,Dennis Tudtud,Takayuki Ueno,Brigitte Van Eyll,Mirta Varela,Nikola Vasev,Damir Vrbanec,Xiaojia Wang,Liwei Wang,Junichiro Watanabe,David Waterhouse,Birgitta Wesenberg,Duncan Wheatley,Zee Wan Wong,Sanjay Yadav,Denise A. Yardley,Tsz-Kok Yau,Winnie Yeo,Cheng Ying,Do Youn Oh +221 more
TL;DR: The end-of-study analysis of CLEOPATRA found progression-free and overall survival were significantly improved in the pertuzumab group compared with the placebo group, and the overall survival rates were also significantly improved.
Journal ArticleDOI
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.
Angelo Di Leo,Guy Jerusalem,Lubos Petruzelka,Roberto Torres,Igor Bondarenko,Rustem Khasanov,Didier Verhoeven,Jose Luiz Pedrini,Iya Smirnova,Mikhail Lichinitser,Kelly Pendergrass,Luca Malorni,Sally Garnett,Yuri Rukazenkov,Miguel Martin +14 more
TL;DR: Fulvestrant is a pure estrogen receptor (ER) antagonist devoid of the agonistic properties displayed by tamoxifen in some tissues (1,5,8) as discussed by the authors.
Journal ArticleDOI
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Javier Cortes,Sung-Bae Kim,W-P. Chung,Seock-Ah Im,Yeon Hee Park,Roberto Hegg,Min Hwan Kim,Ling Ming Tseng,Vanessa Petry,Chi-Feng Chung,Hiroji Iwata,Erika Hamilton,Giuseppe Curigliano,Bing Xue,Chiun-Sheng Huang,Jee Hyun Kim,Joanne Chiu,Jose Luiz Pedrini,Caleb Lee,Yali Liu,Jillian Cathcart,Emarjola Bako,Sunil Verma,Sara A. Hurvitz +23 more
TL;DR: Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of disease progression or death was lower among those who received trastudumab deruxtecan than amongThose who receivedtrastuzuab emtansine.
Journal ArticleDOI
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
Giampaolo Bianchini,Lajos Pusztai,Tadeusz Pienkowski,Yunjoo Im,Giulia Valeria Bianchi,L-M Tseng,MC Liu,A. Lluch,Eugenia Galeota,Domenico Magazzu,J. de la Haba-Rodríguez,D-Y. Oh,Brigitte Poirier,Jose Luiz Pedrini,Vladimir Semiglazov,P. Valagussa,Luca Gianni +16 more
TL;DR: The immune system modulates response to therapies containing trastuzumAB and pertuzumab, and greatest benefit from THP is observed for low expression of some immune markers (i.e. MHC1, CTLA4).
Journal ArticleDOI
Effect of Once-Weekly Epoetin Beta on Survival in Patients With Metastatic Breast Cancer Receiving Anthracycline- and/or Taxane-Based Chemotherapy: Results of the Breast Cancer—Anemia and the Value of Erythropoietin (BRAVE) Study
Matti S. Aapro,Robert C. F. Leonard,Agustí Barnadas,Maurizio Marangolo,Michael Untch,Nikolaos A. Malamos,Jose I. Mayordomo,Dietmar Reichert,Jose Luiz Pedrini,Lidia Ukarma,Armin Scherhag,Hans-Ulrich Burger +11 more
TL;DR: In patients with MBC receiving chemotherapy and initial Hb less than 12.9 g/dL, epoetin beta increased Hb, but did not significantly improve QoL in this study where patients had a high baseline Hb value.